Instructions for Nookam (Cinnarizine, Piracetam) 60 capsules
English product name
NooKam
Release form
Capsules
Description Nookam:
Capsules size №0, with a white body and a blue cap;
The capsule contents are white to white powder with a creamy shade of color.
1 cap.
Piracetam 400 mg
cinnarizin 25 mg
Auxiliary substances:
lactose (milk sugar),
silica colloidal (aerosyl),
magnesium stearate.
Capsule composition:
gelatin is pharmaceutical, glycerol,
propyl parahydroxybenzoate (nipazol),
methylparahydroxybenzoate (nipagin),
sodium lauryl sulfate,
water purified,
diamond blue dye
ATC codes Nookam
N06BX Other psychostimulants and nootropic drugs
Clinical-pharmacological groups / Group affiliation
Drug that improves blood circulation and brain metabolism
Active substance
Piracetam
cinnarizin
Pharmacotherapy group:
Nootropic agent
Testimony Piracetam
Impaired cerebral circulation (ischemic stroke, recovery period after hemorrhagic stroke); encephalopathy in portal hypertension; comatose and subcomatose states after intoxication and brain injuries; CNS diseases accompanied by a decline in intellectual and mental functions; depression; Psychoorganic syndrome with the predominance of signs of asthma and adinamia; asthenia of psychogenic origin; labyrinthopathy;
Meniere syndrome; Intellectual development of children is lagging behind; Prevention of migraines and kinetosis.
Method of use, course and dosage Piracetam:
Inwards, for adults - one to two single doses three times a day; Children - one to two doses once - twice a day
Application for kidney disorders Cinnarizine
The preparation is contraindicated for use in the event of a disorder in the kidney function
Use in liver disorders
The preparation is contraindicated for use in the event of a liver failure
Use in children Cinnarizine
Contraindications are children under 5 years of age.
- Nosology Piracetam (ICD codes)
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- F32
- Depressive episode
- F33
- Recurrent depressive disorder
- F41.2
- Mixed anxiety and depressive disorder
- F48.0
- Neurasthenia
- F79
- Mental retardation unspecified
- G43
- Migraine
- G45
- Transitory cerebral ischemic attacks [attacks] and related syndromes
- H81.0
- Ménière's disease
- H83.2
- Labyrinthine dysfunction
- I63
- Brain infarction
- I69
- Effects of cerebrovascular disease
- K72
- Liver failure not classified in other rubrics (including hepatic coma, hepatic encephalopathy)
- T75.3
- Motion Motion Sickness
- T90
- Effects of head injuries
Pharmacological effect Cinnarizine:
A combined drug with a pronounced antihypoxic, nootropic and vasodilating effect.
Piracetam activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating glucose utilization by cells and increasing their resistance to hypoxia; improves interneuronal transmission in the CNS, improves regional blood flow in the ischemized zone.
Cynnarizine is a selective blocker of slow calcium channels, reduces the entry of Ca2+ cells into the plasma depot, reduces the tone of smooth arteriole muscles, reduces their reaction to biogenic vasoconstrictors (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin, serotonin). It has a vasodilating effect (especially in relation to cerebral vessels, enhancing antihypoxic action of Piracetam), without having a significant effect on the aforesaid. It exhibits moderate antihistamine activity, reduces the excitability of vestibular apparatus, lowers the tone of sympathetic nervous system. Said invention makes it possible to increase the elasticity of erythrocyte membranes, the deformation ability thereof and to reduce blood viscosity.